IDOR 1142 0810
Alternative Names: IDOR-1142-0810Latest Information Update: 28 Feb 2025
At a glance
- Originator Idorsia Pharmaceuticals
- Class Bacterial vaccines; Glycoconjugates; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Klebsiella infections
Most Recent Events
- 28 Jan 2025 Preclinical trials in Klebsiella infections in Switzerland (Unspecified route)
- 15 Jan 2025 IDOR 1142 0810 is available for licensing as of 15 Jan 2025. https://www.idorsia.com/our-innovation/portfolio/portfolio-overview
- 15 Jan 2025 Idorsia Pharmaceuticals plans a clinical trial for Klebsiella infections